Sunshine Biopharma Inc. Cash Flow Statement
SBFM|14 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Sunshine Biopharma Inc. used $13M in operating cash flow and negative free cash flow of $14M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$5.1M | -$4.5M | -$26.7M | -$12.4M | -$2.8M | -$1.7M | -$2.2M | -$1.0M | -$3.5M | -$1.7M | -$1.9M | -$2.5M | -$650.1K | -$650.1K |
| Depreciation & Amortization | $223.5K | $149.1K | $25.2K | $12.7K | $14.1K | $13.8K | $49.4K | $6.6K | $60.7K | $4.3K | $0 | - | - | - |
| Operating Cash Flow | -$12.5M | -$8.8M | -$5.2M | -$1.8M | -$657.3K | -$495.8K | -$512.8K | -$543.5K | -$314.2K | -$867.6K | -$538.6K | -$564.4K | -$393.1K | -$348.3K |
| Capital Expenditures | $1.7M | $82.3K | $194.0K | $0 | $1.2K | $860 | $18.9K | $3.7K | $3.4K | $4.8K | $0 | - | - | - |
| Free Cash Flow | -$14.2M | -$8.9M | -$5.4M | -$1.8M | -$658.5K | -$496.7K | -$531.7K | -$547.2K | -$317.6K | -$872.4K | -$538.6K | - | - | - |
| Share Buybacks | $3.1M | $541.1K | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | -40.7% | -36.8% | -125.2% | -800.8% | -922.1% | -2351.5% | - | - | - | -51079.5% | - | - | - | - |